Ever Play 20 Questions with a Referring Physician?
At least one radiologist is tired of ED physicians asking 20 questions after every scan. Do you share his pain?
I have this conversation at least once a year:
“Hi, it’s Dr. Smith from the ED. Just wanted to follow up on that abdominal CT we ordered on Jane Doe.”
“Oh, yes…I signed that report awhile ago. Normal scan.”
“It’s normal? Because she had right lower quadrant pain.”
“Yeah, I saw that in the clinical history…nothing to account for the pain.”
“No appendicitis?”
“No, appendix looks totally normal.”
“No abscess? No obstruction?”
“Nope, nothing-normal study.”
“No colitis, nothing like that?”
“No. Normal study.”
“Hmm. No ovarian cyst or other badness in the adnexa?”
“No. Nothing. Normal scan.”
“Nothing, huh? No stone in the kidney or ureter?”
If you’ve ever had the dubious pleasure of participating in one of these little exercises, you’ve surely found yourself considering some of the sarcastic replies that I have fought to suppress (thus far, successfully).
For instance:
“Oho! You got me…I was trying to keep the stone a secret. Can’t fool you, can I?”
“Well, yes, there’s appendicitis since you asked, but aside from that the study’s normal.”
“No, when I said ‘normal,’ I meant it. But don’t let that stop you-there are at least six more diagnoses in the differential for this patient’s clinical history! Can you name them all?”
“I’m sorry, you’ve already used up your twenty questions for this patient; I have to move on to the other ten STAT full-body scans you ordered.”
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Expanded FDA Approval Allows Use of Pluvicto Prior to Chemotherapy in Patients with mCRPC
March 28th 2025Recent research demonstrated a 59 percent reduced risk of progression or death with the radioligand therapy Pluvicto in comparison to a change of androgen receptor pathway inhibitor (ARPI) for patients with metastatic castration-resistant prostate cancer (mCRPC).
